迪瑞医疗(300396) - 2025 Q3 - 季度财报

Financial Performance - Revenue for Q3 2025 was CNY 118,056,019.80, a decrease of 60.27% compared to the same period last year[5] - Net profit attributable to shareholders was CNY -58,941,976.28, a decline of 315.63% year-on-year[5] - The company reported a basic and diluted earnings per share of CNY -0.2161, down 315.67% from the previous year[5] - Total operating revenue for the current period was ¥468,750,514.30, a significant decrease from ¥1,175,445,053.92 in the previous period, representing a decline of approximately 60%[35] - Operating profit for the current period was a loss of ¥93,467,863.32, compared to a profit of ¥214,106,161.38 in the previous period[36] - Net profit for the current period was a loss of ¥87,253,663.92, contrasting with a net profit of ¥192,566,604.72 in the previous period[36] - The total comprehensive income for the period attributable to the parent company was -82,064,717.11 yuan, compared to 193,444,937.30 yuan in the previous period[37] - The basic and diluted earnings per share for the current period were both -0.3200 yuan, down from 0.7062 yuan in the previous period[37] Cash Flow - Cash flow from operating activities showed a net outflow of CNY -58,210,987.00, an increase of 80.56% in outflow compared to the previous year[5] - The net cash flow from operating activities increased by CNY 241.16 million, a growth of 80.56%, mainly due to reduced procurement payments and controlled operating expenses[24] - Cash inflows from operating activities totaled 708,497,319.40 yuan, a decrease of 22.2% from 911,446,107.42 yuan in the previous period[38] - Cash outflows from operating activities amounted to 766,708,306.40 yuan, down from 1,210,818,059.95 yuan in the previous period[39] - The net cash flow from operating activities was -58,210,987.00 yuan, an improvement from -299,371,952.53 yuan in the previous period[39] - The net cash flow from investing activities decreased by CNY 272.69 million, a decline of 3627.79%, primarily due to increased cash payments for purchasing structured deposits[24] - The net cash flow from investing activities was -265,176,908.77 yuan, compared to a positive cash flow of 7,516,792.34 yuan in the previous period[39] - The net cash flow from financing activities increased by CNY 58.83 million, a growth of 64.45%, mainly due to a decrease in dividend payments compared to the previous year[24] - Cash inflows from financing activities were 425,000,000.00 yuan, significantly higher than 115,000,000.00 yuan in the previous period[39] - The net cash flow from financing activities was -32,445,646.99 yuan, an improvement from -91,270,818.77 yuan in the previous period[39] Assets and Liabilities - Total assets decreased by 10.38% to CNY 2,784,841,089.87 compared to the end of the previous year[5] - Total assets decreased to ¥2,784,841,089.87 from ¥3,107,533,388.27, reflecting a decline of approximately 10.4%[33] - Total liabilities decreased to ¥889,037,469.80 from ¥1,058,764,060.35, showing a reduction of about 16%[33] - Current liabilities totaled ¥478,180,089.99, down from ¥697,309,012.71, indicating a decrease of approximately 31.4%[33] - Non-current assets decreased to ¥1,074,164,186.50 from ¥1,263,422,546.45, representing a decline of about 15%[33] Shareholder Information - The total number of common shareholders at the end of the reporting period was 16,848[27] - The largest shareholder, Shenzhen Huadexin Run Equity Investment Enterprise, holds 28.34% of shares, amounting to 77,288,400 shares, with 45,600,156 shares pledged[28] Operational Adjustments - The company adjusted pricing policies for key models in response to market competition, impacting short-term sales and profits[8] - The company experienced a 60.12% decrease in operating income due to market environment impacts and business model adjustments[20] - The company aims to conduct a "100-day campaign" in Q4 to improve performance and address challenges[8] - The company reported a significant increase in cash flow from operations, indicating improved operational efficiency and cost control measures[24] Other Financial Metrics - Financial expenses decreased by 610.54% due to increased interest income from maturing structured deposits[21] - Research and development expenses were ¥74,028,362.03, down from ¥95,643,187.59, indicating a reduction of approximately 22.6%[36] - Other comprehensive income after tax for the current period was ¥5,189,997.93, compared to ¥867,601.54 in the previous period, showing a significant increase[36] - The total amount of cash and cash equivalents at the end of the reporting period was CNY 235.01 million, down from CNY 586.68 million at the beginning of the period[31] - The accounts receivable decreased from CNY 441.69 million at the beginning of the period to CNY 335.81 million at the end of the period[31] - The company had a total of 436,936 restricted shares at the end of the reporting period, with 16,382 shares released from restrictions during the period[29] Audit Status - The company’s third-quarter financial report was not audited[41]